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Abstract
Background: While it is estimated that for every maternal death, 20–30 women suffer morbidity, these estimates
are not based on standardized methods and measures. Lack of an agreed-upon definition, identification criteria,
standardized assessment tools, and indicators has limited valid, routine, and comparable measurements of maternal
morbidity. The World Health Organization (WHO) convened the Maternal Morbidity Working Group (MMWG) to
develop standardized methods to improve estimates of maternal morbidity. To date, the MMWG has developed a
definition and provided input into the development of a set of measurement tools. This protocol outlines the pilot
test for measuring maternal morbidity in antenatal and postnatal clinical populations using these new tools.
Methods: In each setting, the tools will be piloted on approximately 250 women receiving antenatal care (ANC)
(at least 28 weeks pregnant) and 250 women receiving postpartum care (PPC) (at least 6 weeks postpartum). The
tools will be administered by trained health care workers. Each tool has three modules as follows:
1. personal history – socio-economic information, and risk-factors (such as violence and substance abuse)
2. patient symptoms – WHO Disability Assessment Schedule (WHODAS) 12-item, and mental health
questionnaires, General Anxiety Disorder, 7-item (GAD-7) and Personal Health Questionnaire, 9-item (PHQ-9)
3. physical examination – signs, laboratory tests and results.
Discussion: This pilot (planned for Jamaica, Kenya and Malawi) will allow for comparing the types of morbidities
women experience between and across settings, and determine the feasibility, acceptability and utility of using a
modified, streamlined tool for routine measurement and summary estimates of morbidity to inform resource
allocation and service provision. As part of the post-2015 Sustainable Development Goals (SDGs) estimating and
measuring maternal morbidity will be essential to ensure appropriate resources are allocated to address its impact
and improve well-being.
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Plain English summary
While there has been a lot of attention to preventing
women from dying during pregnancy and childbirth, less
attention has been paid to women who survive preg-
nancy but have health problems. We developed a tool to
collect information on the kinds of health problems
women may have during pregnancy. This tool includes
questions on the woman’s pregnancy history; how she
feels (emotionally and physically); and an examination.
The tool will be tested in three countries (Jamaica,
Kenya and Malawi). Approximately 1500 women, who
are currently pregnant (28 weeks) or who recently had a
birth (six weeks ago), will be asked to participate in testing
the tool. Most questions and the examination, are part of
normal care for pregnant women. We will analyse the
information collected with the tool to understand the
most common conditions women experience in each of
the three countries, and to figure out the best ways to
measure the problems women may experience related to
pregnancy. We will share results of this project with the
facilities where we conducted the study as well as with the
health and academic communities.
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Background
Improving maternal health and reducing related mortality
have been key concerns of the international community,
particularly as part of the 5th Millennium Development
Goal (MDG-5) and now of the 3rd Sustainable Develop-
ment Goal (SDG-3) [1, 2]. However, maternal mortality
accounts for only a small fraction of the overall burden of
poor maternal health as it excludes maternal morbidity.
The true extent and burden of maternal morbidity is not
known. It has been suggested that for each maternal death,
20 or 30 women suffer from maternal morbidity [3, 4].
However, these calculations are not based on standardized,
well-documented, or transparent methodologies. There
have been significant recent advances in monitoring and
improving women’s quality of care related to severe mater-
nal morbidity, or near-miss events [5]; however accurate
and routine measurements of less-severe maternal mor-
bidity are lacking. Better measures to document and
monitor maternal morbidity will help inform policy and
program decisions and resource allocations to improve
maternal health. This protocol describes a study aiming to
develop and test a tool to measure maternal morbidity
during the antenatal and postpartum periods. The tool
was developed by the Maternal Morbidity Working Group
(MMWG) established by World Health Organization
(WHO) to improve conceptual and operational under-
standing of maternal morbidity.
Defining maternal morbidity
The MMWG, composed of medical professionals,
researchers, country programme implementers, and
patient advocates, was brought together to develop a
definition, identification criteria, a tool and indicators
to systematically measure maternal morbidity. Figure 1
visually details the continuum of outcomes from healthy
pregnancies to death [6]. The objective of the MMWG
was to capture the less severe parts of the morbidity
spectrum, excluding mortality and maternal near miss.
The detailed methodology of the group’s work is docu-
mented elsewhere [7].
Based on a consensus process, the MMWG developed
and adopted the following operational definition of mater-
nal morbidity: “any health condition attributed to and/or
complicating pregnancy, and childbirth that has a negative
impact on the woman’s wellbeing and/or functioning” [4].
The MMWG operationalized this definition by creating a
maternal morbidity matrix (Additional file 1: Table S1;
Additional file 2: Table S2; Additional file 3: Table S3;
Additional file 4: Table S4). The matrix was informed by lit-
erature reviews, and the tenth revision of the International
Statistical Classification of Diseases and Related Health
Problems (ICD-10), including the WHO Application of
ICD-10 to deaths during pregnancy, childbirth and the
puerperium: ICD-Maternal Mortality (ICD-MM) [4, 8].
Setting the foundation for the measurement tools:
operationalizing the maternal morbidity definition
The matrix highlights three dimensions of maternal
morbidity which create the foundation for the meas-
urement tools. The first dimension is composed of
121 conditions, 58 symptoms, 29 signs, 44 investiga-
tions and 35 management strategies. The following
criteria were developed and agreed upon for inclusion
in the matrix:
1) Conditions associated with a negative maternal
outcome that are either exclusive to pregnancy,
childbirth, or the postpartum state,
2) Conditions that occur in >0.1 % in pregnancy;
3) Conditions that are not exclusive to pregnancy,
childbirth, or postpartum but which occur more
frequently during pregnancy (i.e. pregnancy is a risk
factor for the condition).
The identified conditions are grouped in line with the
ICD-MM, with the intent of showing how data on signs,
symptoms, investigations and management strategies may
be aggregated together and to ensure continuity between
the spectrum of morbidity through mortality [8].
The second dimension of the matrix measures func-
tional impact and disability related to pregnancy, as de-
fined in the International Classification of Functioning,
Disability and Health (ICF), and is measured using the
WHO Disability Assessment Schedule 2.0 (WHODAS
2.0) [9, 10]. The WHODAS covers six domains in line
with ICF (cognition, mobility, self-care, getting along, life
activities and participation) and produces standardized
disability levels and profiles using a short, simple and
easy to administer 12-item questionnaire [10].
The third dimension measures maternal history, focus-
ing on social- and health-related characteristics, which
might help identify the maternal morbidity as well as influ-
ence the risk and severity of the morbidity. Some examples
include socio-economic status, pre-existing health condi-
tions, and care seeking during pregnancy. These measures
allow for a more comprehensive understanding of the
“woman as a whole”.
Development of maternal morbidity measurement tools
Based on the matrix, a set of tools was developed to meas-
ure maternal morbidity at two time periods - one to admin-
ister during antenatal care (ANC) and another during
postpartum care (PPC). Wherever possible, previously vali-
dated scales were used such as the WHODAS 12-item for
functioning, the 7-item Generalized Anxiety Disorder
(GAD-7) scale and the 9-item Patient Health Question-
naire (PHQ-9) diagnostic instruments for anxiety and
depression, respectively [10–12].
The study is designed to pilot the tool to:
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1. determine the feasibility, acceptability and utility of
implementing a modified, streamlined tool for
measurement and summary estimates of morbidity
to inform resource allocation and service provision
2. compare the types of morbidities women experience
between and across settings.
Methods
Study design
The study will be cross-sectional, providing a snapshot
of maternal morbidity in two study populations (ANC
and PPC) in three country settings (Jamaica, Kenya and
Malawi). The study will involve the administration of a
questionnaire (the aforementioned maternal morbidity
tool, presented in Additional files 5 and 6) at the appropri-
ate visit where women are already coming to the facility
for care.
To describe the different types of morbidity, and strati-
fication by country setting and time of administration
(ANC vs PPC), 500 women per country (250 each for
ANC and PPC), were deemed adequate for capturing a
range of morbidities. Without pooling the data across
sites or populations, we will have a 6 % margin of error.
Tool development and data quality
A systematic literature review was conducted to identify
existing tools and scales to measure aspects of maternal
morbidity. Existing measures were brought together to
ensure all elements of the maternal morbidity matrix
were covered. A draft version of the tool was then
reviewed by the Principal Investigators (PIs) from each
site, for applicability and feasibility, including the burden
on participants. Mock interviews were conducted in
each setting to evaluate the flow, content and timing for
administering the tool. These mock interviews provided
preliminary information on the questions in the tool and
participant burden. In each of these steps, the question-
naire was further refined and streamlined.
The final pilot questionnaire includes three sections: 1)
woman’s history, 2) current symptoms, and 3) a physical
examination, including a brief review of her medical re-
cords, where available. The tools will focus on the index
pregnancy and the woman’s perception of her pregnancy
and health. The physical examination will include: a
general overview, breast, abdominal, obstetric (for ANC
patients) and pelvic (where appropriate) evaluations, in
line with routine ANC and PPC examinations.
Each country pilot will be led by local investigators
who will be responsible for adapting and, where appro-
priate, translating the questionnaires to ensure their
validity and reliability in the study area.
Enrolment, training and consent
Women attending designated facilities for routine maternal
health care will be invited to participate in the study.
Women for the ANC tool will be invited to participate if
they are in their third trimester of pregnancy (28 or more
weeks). Women for the PPC tool will be invited to par-
ticipate if they are approximately 6 or more weeks post-
partum. A convenience sampling strategy will be used
so that all eligible women will be invited to participate
until 250 women are interviewed for each tool (ANC
and PPC). Data collection is anticipated to last 2 months
at each site.
All pregnancies










Fig. 1 Maternal morbidity and disability spectrum [6]
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Local investigators will recruit, train, and supervise
data collectors. Data collectors will be compensated for
their participation in the research. As part of the training
process in each country, teams will carefully review each
question and conduct mock interviews with training
participants (data collectors) who have experience in
both ANC and PPC service delivery. The team will
check the final version and update the consent forms as
needed based on these experiences.
Training will emphasize the importance of informed
consent and procedures to reduce the risk of interviewers
coercing patients to participate in this study. Data collec-
tors trained specifically for this project, will administer
informed consent forms (verbal and paper based) to eli-
gible women. Participation will be completely voluntary
and non-participation will not affect a woman’s access to
or the type of care due to her. This will be expressed to all
potential participants during both recruitment and the
informed consent session. Additionally, informed con-
sent will ask for access to the woman’s medical records,
those available at the facility and those she brings with
her (mother-baby book, etc). If the woman is unable to
give consent due to mental or physical impairment, she
will not be asked to participate in the study. Addition-
ally, data collectors will be trained to exclude minors
under the age of 15.
The data collectors will also be responsible for referring
women to appropriate services when their answers and/or
physical exam deem it necessary. The local research team
will identify the most appropriate places for referring
women, in accordance with local standard of care. In cases
where referrals will need to be outside of the facility where
data collection is taking place, local PIs will contact the re-
ferral sites to confirm that the services are available prior
to commencing data collection. Local supervisors will
monitor and conduct random checks of interviewers to en-
sure informed consent and appropriate referral procedures
are being followed.
The team expects that each woman’s interview will
last approximately 45 to 65 min total for the adminis-
tration of the tool. The physical exam should take
between 15 to 25 min, while the interview portion of
the questionnaire should take approximately 30 to
40 min. Information being sought on the PPC tool is
more comprehensive than the routinely collected data
at standard postpartum visits and participants will be
informed of this during the consent process.
Data management and statistical analysis
Data collectors will receive and be trained to use a tablet
for administering the questionnaire/tool and entering
the woman’s data. The tablets will support prompt data
collection, transmission, verification, storage and analysis.
In addition to the tablets, data collectors will have access
to paper forms of the tool, as back up. All tablets will be
password protected to ensure confidentiality. Project data
will be inputted into electronic forms of either the ANC
or PPC survey using Open Data Kit (ODK) an open
source data management application on the tablets. The
uploaded data will not include any identifying information
on the woman, and only an ID number will be used to
identify participants. Data from the tablets will be
uploaded to a secure, password protected cloud-based
storage system owned by WHO (https://whodcp.org).
This system allows for both data entry and uploading
and remote review and management of collected data.
Using tablets for administration of the tool will help
ensure data quality with range checks and reduce mistakes
associated with manual data entry. Real-time uploading of
data to a cloud server will ensure data quality is continu-
ally monitored, by the local team and at WHO. The team
based in Geneva, in conjunction with site coordinators
and PIs, will be responsible for the data analysis. The
process will begin while data collection is still on-going in
order to assess progress and determine any data collec-
tion problems and/or patterns. Once data collection and
clean-up are complete the team will perform in-depth
analyses using STATA analytical software in order to
synthesize and present results. In addition to the
Geneva-based team, core MMWG members will be in-
volved in interpreting the data and providing expertise
when necessary.
Ethical considerations
Ethical approval for this study was provided by the WHO’s
Research Ethics Review Committee (ERC) as well as by
the RHR Research Project Panel (RP2), the external review
body of the Department of Reproductive Health, and
Research (RHR) including the UNDP/UNFPA/WHO/
World Bank Special Programme of Research, Development,
and Research Training in Human Reproduction (HRP)
(Additional file 7). Furthermore, relevant entities at each of
the three country sites also provided approval.
There will be no risk to the women who decide not to
participate in the study, they will receive the same stand-
ard of care as those who participate in the study. For
women who chose to participate, this study may cause
some discomfort in terms of the routine physical exams,
or when answering personal questions if they are associ-
ated with negative experiences (i.e. medical and obstetric
history questions about domestic violence or psycho-
logical issues). Potential benefits for participants include
possible diagnosis and treatment for any reported mor-
bidity or other condition.
Only the study team will have access to the information
collected and it will remain confidential. Site coordinators
will work in conjunction with data collectors to protect
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participant anonymity. All participants will receive a small
token of appreciation for their participation.
Discussion
Data gathered from this effort will provide better infor-
mation as to the breadth and depth of pregnancy-related
morbidity and disability in the three study settings. By
identifying current gaps in the care of pregnant women,
this study can enable researchers, policymakers and health
professionals to inform program and resource planning to
address women’s reproductive health needs. This study
will pilot and assess the feasibility of employing a tool to
measure the health consequences of pregnancy. This pilot
study is a step towards finding such a tool and will provide
evidence for the first standard global definition and classi-
fication of non-severe maternal morbidity. Ultimately, the
goal of this project is to produce a valid, comparable, and
routine tool for measurement of maternal morbidity.
Plans for dissemination and use of project results
When the data analysis is complete, the results will be
disseminated in pilot study countries, as well as through
scientific journal articles. Furthermore, according to the
findings, the tool will be revised, simplified and finalized
as a standard measurement for monitoring maternal
morbidity in country programmes.
Conclusion
This paper describes a study designed to test a tool
measuring the impact pregnancy and childbirth have on
the health of women. We describe the design of the
study, the tool, and how we will invite women to participate
in the study. Also, we discussed ethical issues, including
that even if women refuse to participate, they will still
receive the same care at the facility. Our objective in con-
ducting this study is find out the health conditions women
may experience in the three countries. Based on this study,
we will make changes to the tool so that it can be used to
improve the health care of pregnant women and those who
have recently given birth.
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